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In 2012, Journal of Clinical Microbiology began publishing quarterly biographicalfeatures of pioneers and innovators in clinical microbiology. Of the more than 15
microbiologists who have been proﬁled as of the date of this writing, strong and
common threads among this cohort include expertise in antimicrobial agents and
antimicrobial susceptibility testing (1–4), novel automation systems (5–7), and appro-
priate utilization of the clinical microbiology laboratory (8, 9), just to mention a few. The
following career summary of Thomas F. Smith, Ph.D., is unique in that it represents the
initial Journal of Clinical Microbiology biographical feature primarily focused on a
diagnostic virologist. For some Journal of Clinical Microbiology readers, the following
text may represent a signiﬁcant trip down memory lane to the days when cell lines and
cytopathic effects (CPE) were mainstays of the clinical virology service. On the other
hand, insight from a leading clinical virologist of the past 5 decades may provide
profound educational beneﬁt for a younger readership that may not possess such
perspective.
Thomas F. Smith was born in Mason City, IA, in 1939. His father was employed in
auto sales, auto parts distribution, and farm management, while his mother was a
nurse. Both were strong advocates of education, and Smith attended local elementary
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and high schools. During high school basketball season, he played point guard (the
basketball correlate of the football quarterback), which may have provided a foreshad-
owing for future leadership. Smith characterizes his upbringing as in part traditional yet
allowing for freedom of expression. At a basic level, he was taught to “be on time and
have a strong work ethic.”
Smith furthered his education by moving out of state to attend St. John’s University
in Collegeville, MN. He was graduated in 1961 with a baccalaureate degree in biology.
During Smith’s undergraduate studies, the inevitable question that plagues ﬂocks of
biology majors today also entered his mind: “What are you going to do with a B.S. in
biology?” Smith remembered subsequently sorting out areas of biology with which he
was comfortable. Through the counsel of key microbiology faculty members, the ﬁeld
of microbiology was “something that was fostered in my mind.” While at St. John’s
University, Smith also completed a Reserve Ofﬁcers’ Training Corps program, which
(unbeknownst to him at the time) would eventually provide a platform to discern future
professional goals.
Smith earned his master’s degree from the University of South Dakota in Vermillion
in 1963. He investigated growth characteristics of inﬂuenza virus in Madin-Darby canine
kidney epithelial (MDCK) cells. Smith then entered the U.S. Army as a commissioned
lieutenant in the Medical Service Corps and was stationed at Fort Baker, CA (an outpost
of the Presidio in the San Francisco, CA, area). He served in the Sixth U.S. Army Medical
Laboratory. In retrospect, this provided introductory experience to the reference lab-
oratory paradigm, as this laboratory provided basic offerings for several clients, includ-
ing military operatives in Washington, Oregon, California, and Arizona. The laboratory
at Fort Baker was split into disciplines such as chemistry, hematology, pathology, and
microbiology; it also provided rabies and other virology testing as well as virology
research. Smith additionally noted that within the realm of bacteriology, primary
specimens were plated to primary media at satellite clinics and transported to Fort
Baker in candle jars. The Sixth Army Medical Laboratory also supported efforts to
control sporadic outbreaks of Neisseria meningitidis in Fort Ord (Monterrey Bay, CA), Fort
Lewis (Tacoma, WA), and Fort Huachuca (southeast Arizona). Smith further remarked
that, during his tenure, “Colonel Adrian Mandel [Ph.D.] in our lab encouraged me to get
a Ph.D., as a master’s degree may limit opportunities to direct a clinical laboratory. This
was a big inﬂuence for me to return to graduate school.”
Smith earned a U.S. Army Commendation Medal in 1965 and returned to the
University of South Dakota for doctoral studies from 1966 to 1969. While basic virology
research was pursued, with his dissertation project investigating the inﬂuence of
inﬂuenza virus on MDCK cell membranes under the mentorship of Dr. Charles R. Gaush,
it was during this time that Smith’s professional interests experienced a transition. “I
always had an interest in diagnostic virology,” he said. The inﬂuential Dr. Mandel was
connected to respiratory viruses and preventive medicine researcher Elliot Dick, Ph.D.
(studying at the time at University of Wisconsin—Oshkosh), and was able to facilitate
postdoctoral fellowship opportunities for Smith in Wisconsin, Georgia, and Rochester,
MN. As most wise individuals would do, Smith acted on the advice of his spouse
(wanting to reside closer to Iowa) and began a postdoctoral fellowship at Mayo Clinic
in 1969. Smith entered the Mayo Clinic fellowship with the expectation of being trained
in classical diagnostic virology. Much of the pioneering work in cell culture, cultivation
of viruses, and cytopathic effect in the Mayo Clinic laboratory was established by Ernest
C. Herrmann, Jr., Ph.D., in the early 1960s. This was a paradigm shift away from reliance
upon inoculation of embryonated eggs, inoculation of suckling mice and other animals,
and characterization of distinctive tissue patterns and inclusion bodies by pathologists.
Smith wrote that the Herrmann laboratory was “the ﬁrst nonpublic health laboratory (at
that time) to offer routine, rapid, and speciﬁc diagnostic virology services based on the
use of cell cultures. His laboratory was patterned after the prototypical bacteriology in
that diagnosis, not epidemiology, was focused for patient management. Cell cultures in
virology were similar to differential media in bacteriology; similarly, cytopathic effects
were analogous to colonial morphology.”
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When Smith joined the Mayo Clinic Division of Clinical Microbiology faculty in
1971, the future of diagnostic virology was not ﬁrmly established, as most offerings
were relegated to public health laboratories. Questions regarding the role of clinical
virology (whether for a separate clinical laboratory department, an independent
laboratory, or outsourcing) even surfaced within the largest clinical microbiology
laboratories. Smith possessed the vision of fully integrating the diagnostic virology
service into the clinical microbiology laboratory, stating “I could enhance what was
already present at the end of my fellowship by setting up a virology laboratory the
way I thought it should be run. I had a basic background in virology, so I didn’t have
to carve out a place in the microbiology lab. I could make a career as being a
virologist.” Goal number one was to increase the volume of specimens processed by
the virology service (which, at that time, was staffed by four full-time equivalents
[FTE]). Smith therefore established diagnostic systems in his laboratory for patho-
gens that were not adaptable to conventional bacteriologic media. “When there
was a bacterium that was ignored, it was funneled into my lab.” Most of these
adaptations were based on cell culture (Mycoplasma spp. from past laboratory
experience at the University of South Dakota and Clostridium difﬁcile cytotoxin
assays), although Smith remarked that the reﬁnement of Pneumocystis carinii (now
Pneumocystis jirovecii) immunoﬂuorescence microscopy techniques was timely dur-
ing the advent of the AIDS epidemic in the early 1980s. These innovative means to
an end subsequently afforded Smith the revenue stream to both develop additional
virus assays in his laboratory and promulgate research efforts.
One additional bacterial pathogen brought into the realm of the diagnostic virology
laboratory in the 1970s was Chlamydia trachomatis. Smith noted that “chlamydia was
not recognized as an established STD at that time. Laboratories in California and
Washington did have an interest in trachoma. However, military personnel returning
from Southeast Asia had signs and symptoms of STD, but the diagnosis was being
made largely by epidemiology, rather than the clinical laboratory. When Chlamydia
testing was brought into the laboratory, it eventually became recognized as an STD.”
Laboratories on the west coast began to determine that in vitro host cell susceptibility
to C. trachomatis could be enhanced by irradiation or by chemical agents. Smith then
made the discovery that in vitro detection of C. trachomatis could be signiﬁcantly
enhanced by utilizing McCoy’s cells cultivated on coverslips placed in 1-dram glass shell
vials (10), so that the testing could be adaptable to the clinical laboratory. In retrospect,
Smith remarked that the subsequent combination of low-speed primary clinical spec-
imen centrifugation into chemically treated shell vial cell culture plus iodine staining
was the “gateway to allow for the clinical laboratory to diagnose Chlamydia with a
routine diagnostic test with a turnaround time of 1 to 2 days.” Patrick R. Murray, Ph.D.
(11), senior director of worldwide scientiﬁc affairs, BD Life Sciences, who began a Mayo
Clinic fellowship in 1974, provided commentary on the signiﬁcance of this work: “I think
what was remarkable about Tom’s early career was his systematic approach to deﬁning
optimum culture conditions for Chlamydia and viruses and then integrating this into his
diagnostic virology lab. I was impressed by the fact he was never satisﬁed with the
status quo.” Such adaptations allowed Smith’s laboratory to become the ﬁrst in the
United States to offer testing for C. trachomatis.
A second major professional achievement in Smith’s career involved extrapolation
of shell vial technology to laboratory diagnosis of viral infections in 1983. Many of the
techniques learned from culture and detection of Chlamydia were applied to the
detection of human cytomegalovirus (CMV) and other viruses using the shell vial
technique. Such accomplishments fed his continued passion for virology. Jaber Aslan-
zadeh, Ph.D., director of microbiology, Hartford Health System, recalled that even
though his own past research interests were related to mycology and tuberculosis,
“Tom affected me with his enthusiasm for viruses. You could see how he enjoyed it. He
would do virology for free if he wanted to.” As stated by Smith, the impetus for
conversion of conventional cell culture to shell vial culture was simple. “Nothing is more
important to physicians than to rapidly report accurate results,” he said. The validity and
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improved analytical sensitivity of this emerging application were ascertained in sim-
plistic fashion by blinded studies (12–15) involving independent sections of his labo-
ratory performing conventional cell culture and shell vial culture, respectively. With
respect to detection of CMV intermediate-early antigen, Smith related, “the role of shell
vial for reducing average time of infection to 16 hours from the median 8 days in the
past allowed for rapid detection.” This advancement did not go unnoticed in the clinical
community. The advent of shell vial-based detection of CMV also paralleled the early
years of the AIDS epidemic. Marie-Louise Landry, M.D., director of the clinical virology
laboratory at Yale New Haven Hospital, identiﬁed this discovery as being transformative
and revolutionary. “CMV had been a major untreatable cause of morbidity and mortality
in transplant patients, and conventional culture methods required 1 to 4 weeks for a
result. When ganciclovir became available, the shell vial method provided a CMV
diagnosis in 1 to 2 days that was critical to delivering effective therapy.” Dr. Landry went
on to comment that the application of the shell vial paradigm to other viruses was
extremely beneﬁcial to viral diagnosis because viral antigens could be detected prior to
CPE. In addition, this “was not only faster but a much easier method for those not
trained in classical virology. You do not necessarily need to know the CPE. You just
perform the monoclonal antibody stain.”
Yi-Wei Tang, M.D., Ph.D., chief of the clinical microbiology service at the Memorial
Sloan Kettering Cancer Center, identiﬁed Smith as “a great microbiology crystal ball
player,” implying that he possessed a unique talent to predict where the ﬁeld was
headed, despite not being a day-to-day bench technologist. When asked about this
skill, Smith replied, “As you grow in knowledge and experience, you are able to discern
what is important and what is not. I knew what was important down the line; I knew
what would work and what wouldn’t.” Such thoughts characterized the next major
paradigm shift driven by Smith: the conversion of shell vial and conventional cell
culture to nucleic acid ampliﬁcation-based methods in the 1990s. Dr. Tang put it
succinctly: “If no Tom Smith, no modern clinical virology laboratory.” One of the ﬁrst
clinical scenarios beneﬁting from this change involved detection of herpes simplex
virus from cerebrospinal ﬂuid in patients with signs and symptoms of encephalitis.
Once again, this paradigm shift was simply related to accuracy and turnaround time.
“More rapid and more accurate results—that’s why we made the conversion to shell
vials and later to molecular diagnostics,” noted Smith.
In conversations that this writer was fortunate to have experienced with Smith
and several of his colleagues, the concept of “data driven” was constantly drilled
home. “If you make decisions based on data, they won’t ask questions,” stated
Smith. Robin Patel, M.D., current chair of the Division of Clinical Microbiology at
Mayo Clinic, learned the importance of the data-driven paradigm during her
postdoctoral training with Smith. “This was back in a day when things were more
subjective and descriptive. Less data were available.” Mark J. Espy, M.S., long-time
research and development technologist for Smith at Mayo Clinic and coauthor of
more than 60 peer-reviewed publications through this collaboration, added, “If you
do not have the data, you cannot just make assumptions.” Using this logic, Smith,
largely with the assistance of LightCycler technology (16–18), converted approxi-
mately 95% of the assays offered by the clinical virology laboratory at Mayo Clinic
to molecular methods performed by a staff that now approximates 40 FTE. (Today,
the Division of Clinical Microbiology at Mayo Clinic includes a staff of more than 250
FTE [including 8 research and development technologists], many of whom continue
to perform the assays developed by Smith.) This paramount contribution to diag-
nostic virology is viewed by Richard B. (Tom) Thomson, Jr., Ph.D., director of
microbiology laboratories at NorthShore University HealthSystem, as follows: “In the
1990s, the clinical laboratory spoke to the promise of PCR, but very few were doing
it. In the middle 2000s, commercial companies started selling the assays. Tom
spearheaded this whole effort but never really took credit for it. At the same time,
he didn’t want to retire until it was accomplished.”
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When clinical scientists who were interviewed for this biographical feature were
asked to cite lasting contributions and innovations of Smith, to a person the two
paradigms that arose were the aforementioned shell vial culture optimization and
conversion of the clinical virology laboratory to molecular diagnostics. Steven Specter,
Ph.D., professor of molecular medicine at University of South Florida Health, offered a
third: “Tom’s lab was one of only a handful of labs to offer quality training in clinical
virology, and he produced a large number of trainees in clinical virology.” Early during
his tenure, Smith assumed directorship of the second-oldest American Society for
Microbiology Committee on Postgraduate Educational Programs-approved fellowship
program (CPEP) in the United States and fostered the program through a number of
reaccreditation exercises. He estimates having directed the program for 12 to 15 years
and having trained more than 2 dozen fellows (most of whom currently direct clinical
microbiology laboratories). Smith noted that the fellowship experience also proved to
be of beneﬁt to faculty, as “these people were already trained as Ph.D.s and were
capable of bringing another (laboratory) method into Mayo. These individuals were
always very bright and challenged us. They made the laboratory more exciting.” In
addition to CPEP, Mayo Clinic facilitated an American Board of Pathology training
program in medical microbiology, with Smith serving in a mentorship capacity for
dozens of additional fellows. Qualities that Smith attempted to instill in these world-
wide trainees included honesty and fairness, integrity, a strong work ethic, and patient-
centered care. “If the patient comes ﬁrst, then decisions are easy. It takes you (and your
interests) out of the equation, other than being the judge of the best test.” Dr.
Aslanzadeh noted that his 2 years with Smith and the Mayo Clinic CPEP were “two of
the most wonderful years of my life.”
Smith is widely credited with expanding the pedagogic knowledge base of diag-
nostic virology with his more than 230 peer-reviewed publications, ﬁve coauthored
books, 51 book chapters, and hundreds of abstracts. Richard L. Hodinka, Ph.D., chair of
the Department of Biomedical Sciences at the University of South Carolina School of
Medicine in Greenville, stated, “Tom was right at the ground level of diagnostic
virology. He was one of the ﬁrst to write about the clinical use of the diagnostic virology
laboratory and one of the ﬁrst to speak and write about viral rapid diagnostics as they
came of age over the years.” One hallmark publication was the Diagnostic Molecular
Microbiology textbook, published in 1993 (19). Dr. Patel noted, “Tom looked at molec-
ular diagnostics not just as a research tool but also in terms of delivery of care to
patients. This book is reﬂective of his vision to apply molecular diagnostics to clinical
medicine.” Dr. Hodinka added, “At that time, lots of people in academia were starting
to do molecular biology, but there was no book. You had to go to someone’s lab or you
had to go to a workshop. This text provided a very useful service to everyone who was
doing molecular. It provided a basis for quality control and quality improvement that
was involved in molecular testing.” Smith has also served on several editorial boards,
including those for Journal of Clinical Microbiology, Laboratory Medicine, Diagnostic
Microbiology and Infectious Diseases, and Clinical Microbiology Reviews, and served
numerous times as a virology section editor for Manual of Clinical Microbiology. He has
been elected to fellowship in the American Academy of Microbiology and has achieved
diplomate status on the American Board of Medical Microbiology. Drs. Hodinka, Landry,
and Specter hailed Smith’s advocacy of clinical virology at a professional level through
his decades-long association with the Pan American Group for Rapid Diagnosis of Viral
Infections and the Clinical Virology Symposium.
Despite the aforementioned burgeoning list of revolutionary accomplishments,
Smith is largely described as a soft-spoken and humble gentleman. “Tom really
embodied that term,” stated Dr. Specter. “Even when taking an opposing view in public,
he always represented himself in a way that was considerate and professional. He
engendered relationships with colleagues.” Dr. Thomson related, “He was a diligent,
patient scientist. In a very organized way, he decided what needed to be done and did
it. He was always very honest about what he was doing.” To this day, Dr. Thomson
remarks, “Tom has never really aged. He is like a wonderful doting grandfather; he
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always had time for you.” In addition, Dr. Thomson provided the anecdote that,
following his retirement, Smith was commissioned by Mayo Medical Laboratories as “a
good will ambassador” who would travel to microbiology laboratories within Minne-
sota and Wisconsin and assist them in their preparation for upcoming College of
American Pathologists inspections. Mr. Espy remembered that Smith “wasn’t much on
doing things just to see if we could do it. Whatever we did was for the beneﬁt of the
patient.” Dr. Aslanzadeh remarked that at local and national meetings, Smith always
acknowledged those who contributed to a project. “The audience was clear where
this idea came from. He never missed anyone.” Dr. Murray described Smith as “a
man of high integrity—a genuinely warm individual. He was always supportive of
fellows and visitors to the laboratory and always sharing his knowledge.” One
comment intimated to this writer especially seems to personify Smith. When asked
about the potential abandonment of conventional cell culture and shell vial culture
in the clinical virology laboratory (he emphatically declares “deﬁnitely”), Smith
selﬂessly opined, “I’ve never been possessive of a technique I’ve developed. Rather,
I let new data determine if these things can be improved. Let the data make the
decision, rather than be subjective.”
Dr. Smith retired from the Mayo Clinic in 2009. He continues to reside in Rochester,
MN, with Connie, his wife of 56 years. Four daughters and 10 grandchildren (several of
whom have gone on to careers in nursing, teaching, law, and business) live 70 miles to
the north in the St. Paul/Minneapolis metropolitan area. He golfs twice per week, is an
avid baseball fan, and takes in at least one Iowa Hawkeye football game each Novem-
ber (50-yard-line, row 37, at Kinnick Stadium). True to form, this humble, forward-
thinking clinical virology pioneer provides these parting words for the classical virolo-
gist: “Keep an open mind and be data driven.”
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